IGC Pharma, Inc.

Approximately 80% of target participants have completed trial participation, strengthening momentum toward database lock and topline analysis

- Continued Advancement of CALMA Phase 2 Trial -

Research highlights advanced imaging analytics that may support Alzheimer's disease monitoring, patient stratification, and future therapeutic development.

Outreach initiative supports awareness of agitation and patient engagement as enrollment approaches completion

Behavioral neurology expertise and expanded patient access support final phase of recruitment in Alzheimer's agitation study

Authorization provides regulated capability to evaluate emerging therapeutic approaches alongside Phase 2 CALMA trial approaching completion

IGC Pharma reaches 80% enrollment in its Phase 2 CALMA Alzheimer’s trial, advancing toward completion, data readout, and a major clinical catalyst in 2026.

IGC Pharma expands its Phase 2 CALMA Alzheimer’s trial with a new clinical site, strengthening enrollment momentum and advancing its lead therapeutic program

- Strategic Pivot to Pure-Play Biotech -

- Practice integrated neurology network expands enrollment capacity -

- Adds world renowned GNA site to broaden genetic diversity and strengthen path toward 2026 data catalyst -

- Multi-Specialty CNS Research Center Strengthens Trial Execution and Patient Diversity in Alzheimer's Agitation Study -

- Hybrid Trial Model Enhances Participant Access, Retention, and Enrollment Efficiency Across Underserved and Rural Communities -

- New Financing Supports Disciplined Clinical Execution and Value Creation in Alzheimer's Drug Development -

- New Patent Expands IGC Pharma's Pharmaceutical Cannabinoid Portfolio Beyond Alzheimer's Disease -

New Caregiver Resource Showcases Expert Contributions and Reinforces IGC Pharma's Leadership in Alzheimer's Innovation

Company Accelerates Phase 2 Alzheimer's Program and Gains National Institute on Aging (NIA) Recognition for AI Leadership

IGC-1C Targets Tau Protein's Liquid-Liquid Phase Separation (LLPS), Posing a Novel Threat to Neurotoxic Tangles; High Binding Affinity Confirmed

• Positions IGC at the intersection of biotech innovation and cannabinoid science in one of the largest unmet medical needs in the world

• Alzheimer's affects over 50 million people globally, with more than 400 million at risk from underlying disease pathology

- New hope in Alzheimer's: IGC-M3 targets the disease on four fronts, showing promise in cellular models -

- Company to showcase innovations in AI-driven drug discovery and early disease detection, including solutions for low resource settings -